- Price
- $86.00
- Day
- +0.84%
- Mkt Cap
- $804.94M
- 52W Range
- $50.23 – $100.00
- Volume
- 122.7K
- Beta
- 0.67
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Transcat is rated BUY, leveraging a mission-critical, high-retention calibration services business with strong operating leverage and recurring revenue. TRNS delivered robust Q1 FY27 results: revenue rose 22% YoY, service segment operating income surged 35% YoY, and organic service growth was 13% YoY. The stock trades at a 50% discount to its recent EV/EBITDA peak, despite forward EBITDA growth 70% above the industrial sector median.
Read full article
ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical.
Read full article